ID   HMV-I
AC   CVCL_8233
SY   HMV-1
DR   BioSample; SAMN03151710
DR   CGH-DB; 9288-4
DR   ChEMBL-Cells; CHEMBL3308666
DR   ChEMBL-Targets; CHEMBL614825
DR   Cosmic; 874382
DR   Cosmic; 905202
DR   Cosmic; 1007154
DR   PubChem_Cell_line; CVCL_8233
DR   RCB; RCB0004
DR   TKG; TKG 0302
DR   Wikidata; Q54889974
RX   PubMed=3361142;
RX   PubMed=10508494;
RX   PubMed=11416159;
RX   PubMed=15467732;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from female 65 year old patient with vaginal melanoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00126.
CC   Population: African American.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Discontinued: RCB; RCB0004; true.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): PubMed=11416159; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 13.3
ST   D16S539: 9
ST   D18S51: 16
ST   D21S11: 27,28
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 12
ST   FGA: 18,21
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18,19
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=3361142; DOI=10.1111/1523-1747.ep12560926;
RA   Nakamura T., Seki S., Matsubara O., Ito S., Kasuga T.;
RT   "Specific incorporation of 4-S-cysteinylphenol into human melanoma
RT   cells.";
RL   J. Invest. Dermatol. 90:725-728(1988).
//
RX   PubMed=10508494; DOI=10.1002/(SICI)1097-0215(19991112)83:4<555::AID-IJC19>3.0.CO;2-2;
RA   MacLeod R.A.F., Dirks W.G., Matsuo Y., Kaufmann M., Milch H.,
RA   Drexler H.G.;
RT   "Widespread intraspecies cross-contamination of human tumor cell lines
RT   arising at source.";
RL   Int. J. Cancer 83:555-563(1999).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//